Related Experiment Video
Updated: Apr 1, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
[Current progress and future direction of hemophilia treatment]
1Department of Transfusion Medicine, Nagoya University Hospital.
Abstract:
Hemophilia is a rare bleeding disorder, for which treatments are still being developing and several new agents are providing better quality of life for patents. National evidence- and/or practice-based guidelines have been published by JSTH. Recommendations offered for the hemostatic management of hemophilia have assisted healthcare providers in initiating general hemophilia care. This article first reviews the two national guidelines for patients with/without inhibitor treatments. Then, future perspectives on progress in current treatment as well as the newer agents are summarized. Treatment options anticipated to be available in the near future are proposed for all caregivers in Japan.
More Related Videos
09:35Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
06:59The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Microorganisms in Medicine and Therapeutics
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...